DENVER, March 20 /PRNewswire-FirstCall/ -- Accelr8 Technology
Corporation (Amex: AXK) today reported a loss of $456,359 or $0.05 per
share on net revenues of $85,149 for the quarter ended January 31, 2007. In
the comparable three-month period of fiscal 2006, Accelr8 reported a net
loss of $785,545 or $0.08 per share on net revenues of $55,490.
According to David Howson, Accelr8's president, "the reduced losses
reflect the completion of the first BACcelr8r(TM) laboratory prototypes.
We've used them to successfully complete the first pilot study on one of
our three major antibiotic resistance category identification tests. We
will present the results in May at the annual meeting of the American
Society for Microbiology. We've now expanded the study on rapid 'MRSA'
identification -- the most common cause of hospital acquired 'Staph'
infections -- and obtained large bacterial collections for statistical
"In addition, we're progressing with tests to identify the other two
major resistance categories. Both of the additional categories occur in
different bacteria that are more difficult to identify and treat than MRSA.
These serious infections outnumber Staph infections by about 2:1 in the
ICU. Some have also become a serious problem in wound infections with our
military personnel, compounding the terrible injuries they've already
"We've begun the BACcel(TM)-1.0 product development program with
limited objectives to deliver enhanced research prototypes that will
further increase our experimental throughput. We've also begun the process
to obtain human specimens, initially to optimize our sample preparation
"Finally, our microarraying products have received some attention in
the scientific press. An article in Nature on protein microarraying
identified the Schott slides -- licensed from Accelr8 -- as a serious
contender. Also, an academic consortium led by the Scripps Research
Institute has published research on rapid and precise flu virus variant
identification using our slides. We believe that these events show promise
for molecular diagnostics platforms to eventually adopt microarraying,
adding to our total diagnostics business potential," Howson concluded.
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications in
medical instrumentation, basic research, drug discovery, and bio-detection.
Accelr8 is developing a rapid clinical pathogen platform, the
BACcelr8r(TM), based on its innovative surface coatings, assay processing,
and detection technologies. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8's own
SOURCE Accelr8 Technology Corporation